1-(3-bromophenyl)-2-iodoethanone | 1345692-79-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(3-bromophenyl)-2-iodoethanone
• CAS: 1345692-79-6
• 化学式: C₈H₆BrIO
• 分子量: 324.944
• InChiKey: CVWWAGDVPIUJFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(3-bromophenyl)-2-iodoethanone 、 2-氨基苯硫醇 以 二甲基亚砜 为溶剂， 生成 benzo[d]thiazol-2-yl(3-bromophenyl)methanone
  参考文献：
  名称：

  多路径耦合多米诺骨牌策略：无金属氧化环化，从多形式底物一锅合成2-酰基苯并噻唑

  摘要：

  已经开发了一种多途径偶联多米诺骨牌策略，用于通过多种不同的途径从多种形式的底物芳烃，芳基乙炔，2-羟基-芳族酮和甲醇中高效合成2-酰基苯并噻唑。通过逻辑耦合的氧化/杂环多米诺工艺，可以在一锅中合成多种不含金属的2-酰基苯并噻唑。

  DOI：

  10.1021/ol301921t
• 作为产物：
  描述：

  2,3-二溴苯乙酮 在 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 25.0h， 生成 1-(3-bromophenyl)-2-iodoethanone
  参考文献：
  名称：

  N-Phenethyl and N-naphthylmethyl isatins and analogues as in vitro cytotoxic agents

  摘要：

  A range of N-phenethyl, N-phenacyl, and N-(1- and 2-naphthylmethyl) derivatives of 5,7-dibromoisatin 2 were prepared by N-alkylation reactions. Their activity against human monocyte-like histiocytic lymphoma (U937), leukemia (Jurkat), and breast carcinoma (MDA-MB-231) cell lines was assessed. The results allowed further development of structure-activity relationships. The compound 5,7-dibromo-N-(1-naphthylmethyl)-1H-indole-2,3-dione 5a was the most potent against U937 cells with an IC50 value of 0.19 mu M. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.12.026

文献信息

• Oxidative iodination of carbonyl compounds using ammonium iodide and oxone®
  作者：Mahender Reddy Marri、Arun Kumar Macharla、Swamy Peraka、Narender Nama

  DOI：10.1016/j.tetlet.2011.09.106

  日期：2011.12

  A simple, efficient, mild, and regioselective method for oxyiodination of carbonyl compounds has been reported by using NH4I as the source of iodine and Oxone® as an oxidant. Various carbonyl compounds such as aralkyl ketones, aliphatic ketones (acyclic and cyclic), and β-keto esters proceeded to the respective α-monoiodinated products in moderate to excellent yields. Unsymmetrical aliphatic ketones

  通过使用NH 4 I作为碘的来源和Oxone®作为氧化剂，已经报道了一种简单，有效，温和和区域选择性的羰基化合物氧碘化方法。各种羰基化合物（如芳烷基酮，脂族酮（无环和环状）和β-酮酯）以中等至优异的收率发展为各自的α-单碘化产物。不对称脂族酮反应平稳，生成1-碘和3-碘酮的混合物，主要形成1-碘产物。
• A practical synthesis of α-bromo/iodo/chloroketones from olefins under visible-light irradiation conditions
  作者：Zhihui Wang、Lei Wang、Zhiming Wang、Pinhua Li、Yicheng Zhang

  DOI：10.1016/j.cclet.2020.02.022

  日期：2021.1

  Abstract A practical synthesis of α-bromo/iodo/chloroketones from olefins under visible-light irradiation conditions has been developed. In the presence of PhI(OAc)2 as promoter and under ambient conditions, the reactions of styrenes and triiodomethane undergo the transformation smoothly to deliver the corresponding α-iodoketones without additional photocatalyst in good yields under sunlight irradiation

  摘要建立了在可见光条件下由烯烃合成α-溴/碘/氯酮的实用方法。在存在PhI（OAc）2作为促进剂的情况下，并且在环境条件下，苯乙烯和三碘甲烷的反应平稳地进行转化，从而在阳光照射下以良好的收率顺利地递送了相应的α-碘酮，而没有额外的光催化剂。同时，通过使用Ru（bpy）3Cl2作为光催化剂在蓝色LED（450-455 nm）辐射下，苯乙烯与三溴甲烷和三氯甲烷的反应可以高产率产生所需的α-溴代酮和α-氯代酮。
• Substituted imidazo[1,2-A] pyridine derivatives
  申请人：——

  公开号：US20020188128A1

  公开（公告）日：2002-12-12

  The present invention is a series of novel compounds of formula I and a method of treatment or prevention of a mGluR5 receptor mediated disease by administering an therapeutically effective amount of a compound formula 1 wherein R 1 and R 2 are selected from hydrogen, (C 1-6 )-alkyl, halogen, hydroxy, (C 1-6 )-alkoxy and A is defined the description, or a pharmaceutically acceptable salt thereof.

  本发明涉及一系列新颖的化合物，化学式为I，并通过给予有效治疗剂量的化合物化学式1来治疗或预防mGluR5受体介导的疾病的方法，其中R1和R2从氢、(C1-6)-烷基、卤素、羟基、(C1-6)-烷氧基中选择，A在描述中有定义，或其药用盐。
• Substituted imidazo [1,2-a] pyridine derivatives
  申请人：——

  公开号：US20030212096A1

  公开（公告）日：2003-11-13

  The present invention is a series of novel compounds of formula I and a method of treatment or prevention of a mGluR5 receptor mediated disease by administering an therapeutically effective amount of a compound formula 1 wherein R 1 and R 2 are selected from hydrogen, (C 1-6 )-alkyl, halogen, hydroxy, (C 1-6 )-alkoxy and A is defined the description, or a pharmaceutically acceptable salt thereof.

  本发明涉及一系列新型化合物I的方法，以及通过给予化合物公式1的治疗有效量或预防mGluR5受体介导的疾病的方法，其中R1和R2选择自氢，(C1-6)-烷基，卤素，羟基，(C1-6)-烷氧基和A在说明中定义，或其药学上可接受的盐。
• Substituted imidazo[1,2-a]pyridine derivatives
  申请人：——

  公开号：US20040180921A1

  公开（公告）日：2004-09-16

  The present invention is a series of novel compounds of formula I and a method of treatment or prevention of a mGluR5 receptor mediated disease by administering an therapeutically effective amount of a compound formula 1 wherein R 1 and R 2 are selected from hydrogen, (C 1-6 )-alkyl, halogen, hydroxy, (C 1-6 )-alkoxy and A is defined the description, or a pharmaceutically acceptable salt thereof.

  本发明涉及一系列公式I的新化合物以及通过给予公式1中化合物的治疗有效量来治疗或预防mGluR5受体介导的疾病的方法，其中R1和R2选择自氢、(C1-6)烷基、卤素、羟基、(C1-6)烷氧基，A的定义如说明书所述，或其药学上可接受的盐。